Scapula chondrosarcoma A case report

被引:5
作者
Qiang, Shuai [1 ,2 ]
Ma, Xin-Nan [3 ]
Wang, Hong-Wei [3 ]
Lv, Song-Cen [3 ]
机构
[1] Chinese Acad Med Sci, Plast Surg Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Harbin Med Univ, Dept Orthoped, Affiliated Hosp 2, 194 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China
关键词
chondrosarcoma; scapula; tumor;
D O I
10.1097/MD.0000000000015388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Chondrosarcoma is a malignant mesenchymal tumor originating from cartilage. The pelvis, ribs, femur, and humerus are the most frequently affected sites, and scapula involvement is relatively rare. The aim of the present study was to report a case of chondrosarcoma in the scapula. Patient concerns: A 42-year-old woman presented with a 3-month history of a painful mass in the right scapula. Diagnoses and intervention: The patient underwent tumor resection. The post-operative pathological diagnosis was scapula chondrosarcoma. Outcomes: Following resection, the patient continued to receive routine follow-up care. There was no recurrence or tumor metastasis at a follow-up of 5 years. Conclusions: Surgery remains the primary therapy for chondrosarcoma. One of the greatest challenges in the management of chondrosarcoma is to accurately assess tumor grade before surgical intervention. Chemotherapy and radiotherapy have been applied without success. Chemo-and radioresistance have been examined beyond classic phenotypic properties to identify more efficient therapeutic strategies. Therefore, development of future novel therapies is contingent upon elucidating the molecular mechanisms of chondrosarcoma.
引用
收藏
页数:4
相关论文
共 31 条
[1]   A progressively enlarging swelling of the palate [J].
Chauhan, Nidhi P. ;
Pai, Keerthilatha M. ;
Mutalik, Sunil ;
Balakrishnan, R. ;
Valiathan, Manna ;
Sujir, Nanditha .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2014, 117 (02) :132-137
[2]  
Moraes Frederico Barra de, 2014, Rev. bras. ortop., V49, P409, DOI 10.1016/j.rboe.2014.04.020
[3]  
Eduardo SA, 2015, TUMORS TUMOR LIKE LE, P265
[4]  
EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO
[5]  
2-B
[6]   Survival and prognostic factors in conventional central chondrosarcoma [J].
Fromm, Julian ;
Klein, Alexander ;
Baur-Melnyk, Andrea ;
Knoesel, Thomas ;
Lindner, Lars ;
Birkenmaier, Christof ;
Roeder, Falk ;
Jansson, Volkmar ;
Duerr, Hans Roland .
BMC CANCER, 2018, 18
[7]   Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27 [J].
Fukumoto, Singo ;
Kanbara, Kiyoto ;
Neo, Masashi .
ACTA HISTOCHEMICA, 2018, 120 (02) :142-150
[8]   CHONDROSARCOMA .1. A SELECTED LITERATURE-REVIEW [J].
GARRINGTON, GE ;
COLLETT, WK .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1988, 17 (01) :1-11
[9]   Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma [J].
Ghedira, Donia ;
Voissiere, Aurelien ;
Peyrode, Caroline ;
Kraiem, Jamil ;
Gerard, Yvain ;
Maubert, Elise ;
Vivier, Magali ;
Miot-Noirault, Elisabeth ;
Chezal, Jean-Michel ;
Farhat, Farhat ;
Weber, Valerie .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 :51-67
[10]  
Gomes Anna Caroline Nobre, 2006, Radiol Bras, V39, P449, DOI 10.1590/S0100-39842006000600015